Movement Alert｜Twist Bioscience Corp Rises 5.14% in Regular Trading, Analyst Coverage and Lilly TuneLab Collaboration Support Attention

Market Focus10-27

On October 27, Twist Bioscience Corp rose 5.14% in Regular Trading, trading at $152.08 per share, with turnover of $25.5464 million.

The move coincided with continued attention around recent analyst coverage and the company’s previously disclosed collaboration with Eli Lilly’s TuneLab platform.

Publicly available information shows Jefferies initiated coverage with a Hold rating and a $150 price target, while UBS initiated coverage with a Neutral rating and a $144 price target. Earlier, Twist Bioscience Corp said it would provide antibody characterization data services to Lilly TuneLab, an AI/ML drug discovery platform created by Eli Lilly, reinforcing market focus on its role in AI-enabled antibody drug discovery ahead of its next earnings report on November 12.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment